Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-020 + hyperforin
- Development stage
- Unknown
- Lead developer
- Jupiter Wellness
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
DA-020 + hyperforin is a topical combination therapy developed by Applied Biology, Inc. for the prevention of chemotherapy-induced alopecia (CIA). The formulation consists of DA-020, which is a topical solution of the alpha-adrenergic receptor agonist oxymetazoline, and 1.5% hyperforin, a prenylated phloroglucinol derivative found in St. John's Wort. Oxymetazoline acts as a potent vasoconstrictor; when applied to the scalp, it is intended to temporarily reduce local blood flow, thereby decreasing the delivery of systemic cytotoxic chemotherapy agents to the hair follicles. Hyperforin is included for its potential follicular protective effects, possibly mediated through its activity as a TRPC6 channel agonist or its anti-inflammatory properties, which may help maintain hair follicle integrity during chemotherapy treatment.
- Other names
- oxymetazoline + hyperforinDA-020 and HyperforinDA020 and HyperforinDA 020 and Hyperforin
02
Targets
ALOX12 (Arachidonate 12-lipoxygenase, 12S type)DAT (Dopamine plasma membrane transport protein)GABRR (GABA-A receptor subunit rho)PXR (Pregnane X receptor)PGHS-1 (Prostaglandin G/H Synthase 1)TRPC6 (Transient receptor potential canonical type 6)ADRA1A (α1A)ADRA2A (α2A)
Beyond the preview
Go deeper on DA-020 + hyperforin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-020 + hyperforin.